Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib vs Pemetrexed in Advanced NSCLC
NCT00372788Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of selumetinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Disease progression event count at 12 weeks. Started Aug 2006; status: completed.
02
Drugs
selumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00372788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372788.